NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys
Razelle Kurzrock(Medical College of Wisconsin), F. Marc Stewart(Seattle Cancer Care Alliance), Christopher D. Gocke, Robert J. Morgan(Mayo Clinic), Alan P. Venook(University of California, San Francisco), Carlos L. Arteaga(The University of Texas Southwestern Medical Center), Wallace Akerley(University of Utah), John F. DiPersio(Washington University in St. Louis), A. Dimitrios Colevas(Cancer Institute (WIA)), Lee S. Schwartzberg(Renown Health), Anthony J. Olszanski(Fox Chase Cancer Center), Jeffrey W. Clark(Massachusetts General Hospital), Jonathan Tait(Johns Hopkins University), William E. Carson(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), David S. Ettinger(Johns Hopkins University)
Cited by 31
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
|Molecular Cancer Therapeutics|2015|2.3k